Who are Warfarin titrated to an INR of 2.5-3.0's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coumadin, Standard dose oral anticoagulant, Sodium warfarin, Vitamin K antagonist(warfarin), Nadroparin Calcium and Warfarin, Warfarin or coumadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/warfarin-titrated-to-an-inr-of-2-5-3-0.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Warfarin titrated to an INR of 2.5-3.0 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Warfarin titrated to an INR of 2.5-3.0 (Warfarin titrated to an INR of 2.5-3.0) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist. Area: Cardiovascular.

phase 3 Vitamin K antagonist Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Warfarin titrated to an INR of 2.5-3.0 (Warfarin titrated to an INR of 2.5-3.0) — US Department of Veterans Affairs. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Warfarin titrated to an INR of 2.5-3.0 TARGET	Warfarin titrated to an INR of 2.5-3.0	US Department of Veterans Affairs	phase 3	Vitamin K antagonist
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Vitamin K antagonist(warfarin)	Vitamin K antagonist(warfarin)	Joon Bum Kim	marketed	Vitamin K antagonist	Vitamin K epoxide reductase (VKORC1)
Nadroparin Calcium and Warfarin	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist class)

Joon Bum Kim · 1 drug in this class
Population Health Research Institute · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
University Hospital, Bonn · 1 drug in this class
University Hospital, Limoges · 1 drug in this class
Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Warfarin titrated to an INR of 2.5-3.0 — Competitive Intelligence Brief. https://druglandscape.com/ci/warfarin-titrated-to-an-inr-of-2-5-3-0. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab